I am excited about learning more about the how the
Post# of 9144
(Total Views: 452)
Posted On: 05/06/2020 8:46:38 AM
Re: erickarther #5976
I am excited about learning more about the how the test works. I am keeping my fingers crossed that it is something that can be extended to all pathogenic microbes.
Hopefully, we'll get more attention than in the past from the press when the PR comes out. The Vindy article is a nice start. We need more national outlets to spread the news, but I expect this will be difficult given how there have been many companies announcing the development of their own tests to detect SARS-Cov-2.
It'll be important to clearly highlight in layman's terms the differences between THIS test vs. other tests that currently have the attention of the CDC/FDA:
1. The 15-minute antibody tests are inaccurate and not very sensitive. And if you test positive, there's no way of knowing without further testing (the ones referred to in the Vindy article that take 3-5 days).
2. PCR tests look for DNA evidence and while accurate and sensitive, it also cannot determine if you have an active infection or not without further testing.
The Nanologix test:
1. Is fast as it detects the virus in less than one hour.
2. Is accurate.
3. Is sensitive.
4. Can be configured for point-of-care use doctor's office or for individual use (at home).
This comprehensive list is what I've seen Dr. Birx and the CDC say are qualities they are looking for in an effective diagnostic test. I will be disappointed if the coming PR is unable to break thru to garner the attention that it deserves.
Moving onto potential affect to share price, CODX went from a market cap of ~$24M to $380M on news of their test.
Using ~160M shares outstanding, a market cap of $380M translates to a share price of ~$2.38. Lots of potential upside here. Of course, cannot compare apples to apples since CODX is an SEC reporting company whereas NNLX is not.
Dr. James Rogers adds much credibility in lieu of lack of financials. Potential new investors can lean on his joining the Company as Chief Science Officer and his involvement in the development of this test as evidence that NNLX is a 'real' company with legitimate claims.
Hopefully, we'll get more attention than in the past from the press when the PR comes out. The Vindy article is a nice start. We need more national outlets to spread the news, but I expect this will be difficult given how there have been many companies announcing the development of their own tests to detect SARS-Cov-2.
It'll be important to clearly highlight in layman's terms the differences between THIS test vs. other tests that currently have the attention of the CDC/FDA:
1. The 15-minute antibody tests are inaccurate and not very sensitive. And if you test positive, there's no way of knowing without further testing (the ones referred to in the Vindy article that take 3-5 days).
2. PCR tests look for DNA evidence and while accurate and sensitive, it also cannot determine if you have an active infection or not without further testing.
The Nanologix test:
1. Is fast as it detects the virus in less than one hour.
2. Is accurate.
3. Is sensitive.
4. Can be configured for point-of-care use doctor's office or for individual use (at home).
This comprehensive list is what I've seen Dr. Birx and the CDC say are qualities they are looking for in an effective diagnostic test. I will be disappointed if the coming PR is unable to break thru to garner the attention that it deserves.
Moving onto potential affect to share price, CODX went from a market cap of ~$24M to $380M on news of their test.
Using ~160M shares outstanding, a market cap of $380M translates to a share price of ~$2.38. Lots of potential upside here. Of course, cannot compare apples to apples since CODX is an SEC reporting company whereas NNLX is not.
Dr. James Rogers adds much credibility in lieu of lack of financials. Potential new investors can lean on his joining the Company as Chief Science Officer and his involvement in the development of this test as evidence that NNLX is a 'real' company with legitimate claims.
(2)
(1)